Defy Medical’s public materials discuss several hormones and delivery routes for women, including compounded combinations. A prospective patient may therefore be comparing a multi-part program rather than one standardized prescription.
The useful discipline is to ask for the reason behind every component. More hormones, more tests or a customized mixture do not automatically mean better care. The treatment should be explainable in terms of symptoms, evidence, risks and follow-up.
In this entry
Identify the components before comparing programs
Defy’s women’s BHRT guide discusses estradiol, estriol, progesterone, DHEA, pregnenolone and other options, with several routes of administration. It also describes combinations of hormones. These materials show the breadth of the menu; they do not establish which combination is appropriate for an individual.
Ask the clinician to connect each proposed medicine to a defined treatment goal. If several symptoms are present, discuss whether they share a cause or need separate evaluation. A broad program can be harder to interpret if multiple changes happen at once and no one explains how benefit or adverse effects will be assessed.
Check the regulatory status of the finished product
Defy discusses working with compounding pharmacies. A compounded prescription is not FDA-approved, even if an ingredient is found in an approved medicine. A facility’s registration, accreditation or testing statements do not convert the finished preparation into an approved product.
The FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness and quality. ACOG advises against routine use of compounded menopause therapy when appropriate approved options exist. Ask what specific medical need makes a customized preparation necessary in your case, and record that explanation alongside the prescription.
Route and reversibility belong in the discussion
Capsules, topical preparations, injections and long-acting approaches differ in absorption and the ease of changing exposure. If a procedure or long-acting product is proposed, ask where it is administered and how side effects can be managed once it is in place. Telehealth does not make every route a simple home-delivery treatment.
The same hormone name on two products is not enough to establish a safe substitution. Our route guide explains why doses and application instructions must come from the actual prescription, not from another clinic’s website.
Do not lose the uterine-protection question
If systemic estrogen is used and the patient has a uterus, the plan generally needs adequate progestogen protection. A combined topical preparation should not be assumed to provide the same protection as an established regimen merely because progesterone is included in its ingredient list.
Ask what evidence supports the formulation and how bleeding will be evaluated. New postmenopausal bleeding needs medical attention. A hormone program should not encourage you to interpret every unexpected symptom as proof that a dose needs to be raised.
Separate testosterone from the general HRT label
Testosterone for women is a distinct clinical decision, with no FDA-approved formulation specifically indicated for women in the US. A laboratory result alone does not prove that low desire or low energy is caused by testosterone deficiency. The clinician should consider other contributors and explain the evidence for the proposed use.
Monitoring should aim to avoid excessive exposure and identify problems, with clear criteria for changing or stopping treatment. Read the testosterone brief before accepting a broad promise about vitality or anti-aging.
Request a complete financial schedule
We did not verify one all-inclusive menopause program price from the pages reviewed. Request the initial consultation, required laboratory work, medicines, supplies, shipping and follow-up as separate entries. Ask whether outside tests are accepted and which costs recur.
A quoted price for another treatment or a testosterone program should not stand in for your menopause quote. If the plan contains several products, request an itemized price for each so you can discuss both the clinical necessity and the total expense. Use the 90-day worksheet to compare the written proposal.
Our assessment boundary
Defy is a documented provider to investigate for a broad hormone and compounding discussion. Winona offers a different compounded-menu comparison, while Midi helps contrast approved menopause care and a separate testosterone program. We did not audit a pharmacy, undergo treatment or establish better outcomes for any of them. The value of the comparison is in the questions it makes concrete.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.